ASH 2019, Orlando – Belantamab mafodotin is a new myeloma drug that has shown very promising results. The clinical trial Dreamm-3 was presented yesterday at the American Society of Hematology (ASH) Annaul Congress and it is expected to be the European approval trial for this drug.
Dr Katja Weisel, University Medical Center Hamburg-Eppendorf in Germany, explains for Myeloma Patients Europe (MPE) what we need to know about this first-in-class drug.